Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.
Samueli S, Abraham K, Dressler A, Groeppel G, Jonak C, Muehlebner A, Prayer D, Reitner A, Feucht M; Pädiatrisches TSC-Zentrum Wien. Samueli S, et al. Among authors: jonak c. Wien Klin Wochenschr. 2015 Aug;127(15-16):619-30. doi: 10.1007/s00508-015-0758-y. Epub 2015 Apr 10. Wien Klin Wochenschr. 2015. PMID: 25860851 Review.
Mycosis fungoides und Sézary-Syndrom.
Jonak C, Tittes J, Brunner PM, Guenova E. Jonak C, et al. J Dtsch Dermatol Ges. 2021 Sep;19(9):1307-1335. doi: 10.1111/ddg.14610_g. J Dtsch Dermatol Ges. 2021. PMID: 34541808
Mycosis fungoides and Sézary syndrome.
Jonak C, Tittes J, Brunner PM, Guenova E. Jonak C, et al. J Dtsch Dermatol Ges. 2021 Sep;19(9):1307-1334. doi: 10.1111/ddg.14610. J Dtsch Dermatol Ges. 2021. PMID: 34541796 Free PMC article.
Blood will tell: profiling Sézary syndrome.
Jonak C, Brunner PM. Jonak C, et al. Blood. 2021 Dec 16;138(24):2450-2451. doi: 10.1182/blood.2021013433. Blood. 2021. PMID: 34914833 Free article. No abstract available.
Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.
Papadavid E, Kapniari E, Pappa V, Nikolaou V, Iliakis T, Dalamaga M, Jonak C, Porkert S, Engelina S, Quaglino P, Ortiz-Romero PL, Vico C, Cozzio A, Dimitriou F, Guiron R, Guenova E, Hodak E, Bagot M, Scarisbrick J. Papadavid E, et al. Among authors: jonak c. Br J Dermatol. 2021 Nov;185(5):1035-1044. doi: 10.1111/bjd.20588. Epub 2021 Aug 17. Br J Dermatol. 2021. PMID: 34137025
Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K, Jonak C, Woei-A-Jin FJSH, Guenova E, Busschots AM, Bervoets A, Hauben E, Knobler R, Porkert S, Fassnacht C, Cowan R, Papadavid E, Beylot-Barry M, Berti E, Alberti Violetti S, Estrach T, Matin R, Akilov O, Vakeva L, Prince M, Bates A, Bayne M, Wachsmuch R, Wehkamp U, Marschalko M, Servitje O, Turner D, Weatherhead S, Wobser M, Sanches JA, McKay P, Klemke D, Peng C, Howles A, Yoo J, Evison F, Scarisbrick J. Molloy K, et al. Among authors: jonak c. Br J Dermatol. 2020 Mar;182(3):770-779. doi: 10.1111/bjd.18089. Epub 2019 Jul 28. Br J Dermatol. 2020. PMID: 31049926 Free article.
Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT).
Stadler R, Romero PO, Bagot M, Quaglino P, Guenova E, Jonak C, Papadavid E, Stranzenbach R, Sartori D, Musoro JZ, Falato C, Marreaud S, Scarisbrick JJ, Knobler R. Stadler R, et al. Among authors: jonak c. Eur J Cancer. 2021 Oct;156 Suppl 1:S22-S23. doi: 10.1016/S0959-8049(21)00668-7. Eur J Cancer. 2021. PMID: 34649647 No abstract available.
139 results